ESR1 and breast carcinoma: Based on a large number of clinical trial data, patients with ER-high and HER2-negative advanced breast cancer have clearly benefited from CDK4/6 inhibitor combined with endocrine therapy [5–9], but there are still some patients with poor prognosis.